Duodenal levodopa infusion for the treatment of Parkinson's disease.
Expert Opin Pharmacother. 2007.
PMID: 17376020
Review.
Search Page
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
| Year | Number of Results |
|---|---|
| 1974 | 1 |
| 1986 | 1 |
| 1988 | 3 |
| 1989 | 1 |
| 1990 | 1 |
| 1992 | 1 |
| 1993 | 3 |
| 1998 | 1 |
| 2001 | 1 |
| 2002 | 1 |
| 2003 | 1 |
| 2004 | 2 |
| 2005 | 5 |
| 2006 | 6 |
| 2007 | 6 |
| 2008 | 8 |
| 2009 | 12 |
| 2010 | 14 |
| 2011 | 7 |
| 2012 | 9 |
| 2013 | 15 |
| 2014 | 7 |
| 2015 | 8 |
| 2016 | 7 |
| 2017 | 4 |
| 2018 | 3 |
| 2019 | 3 |
| 2020 | 6 |
| 2021 | 2 |
| 2022 | 1 |
| 2024 | 2 |
| 2025 | 1 |
Search Results
128 results
Results by year
Citations
2
articles
found by citation matching
Duodenal levodopa infusion for advanced Parkinson's disease: 12-month treatment outcome.
Mov Disord. 2007.
PMID: 17661426
Clinical Trial.
Search results
Page 1
Duodenal levodopa infusion for the treatment of Parkinson's disease.
Expert Opin Pharmacother. 2007 Apr;8(5):657-64. doi: 10.1517/14656566.8.5.657.
Expert Opin Pharmacother. 2007.
PMID: 17376020
Review.
Motor fluctuations are a common problem in the long-term management of Parkinson's disease (PD), resulting in disability and impaired quality of life. The relatively short serum half-life (approximately 90 min) of oral levodopa/carbidopa and its errati …
Motor fluctuations are a common problem in the long-term management of Parkinson's disease (PD), resulting in disabilit …
PEG-J replacement for duodenal levodopa infusion in Parkinson's disease patients: a retrospective study.
BMC Neurol. 2022 Jan 13;22(1):25. doi: 10.1186/s12883-021-02546-5.
BMC Neurol. 2022.
PMID: 35026993
Free PMC article.
BACKGROUND: Reducing percutaneous endoscopic gastrostomies with jejunal extension tubes (PEG-J) related complications is vital to the long-term preservation of duodenal levodopa infusion (DLI) in advanced Parkinson's disease (APD). Here, …
BACKGROUND: Reducing percutaneous endoscopic gastrostomies with jejunal extension tubes (PEG-J) related complications is vital to the long-t …
Levodopa in the treatment of Parkinson's disease: current status and new developments.
J Parkinsons Dis. 2013 Jan 1;3(3):255-69. doi: 10.3233/JPD-130186.
J Parkinsons Dis. 2013.
PMID: 23948989
Free article.
Review.
Levodopa, a dopamine precursor, is an effective and well-tolerated dopamine replacement agent used to treat Parkinson's disease (PD). ...Recent developments in treatment with levodopa try to obtain continuous delivery with levodopa …
Levodopa, a dopamine precursor, is an effective and well-tolerated dopamine replacement agent used to treat Parkinson's …
Levodopa-carbidopa intestinal gel for treatment of advanced Parkinson's disease.
Curr Med Res Opin. 2011 May;27(5):907-19. doi: 10.1185/03007995.2011.560146. Epub 2011 Feb 25.
Curr Med Res Opin. 2011.
PMID: 21351823
Review.
BACKGROUND: Levodopa is the mainstay of Parkinson's disease (PD) treatment, but is often eventually associated with disabling motor complications in patients with advanced PD. ...Clinical trials indicate LCIG may significantly improve motor comp …
BACKGROUND: Levodopa is the mainstay of Parkinson's disease (PD) treatment, but is often eventually assoc …
Causes of withdrawal of duodenal levodopa infusion in advanced Parkinson disease.
Neurology. 2015 Apr 21;84(16):1669-72. doi: 10.1212/WNL.0000000000001500. Epub 2015 Mar 25.
Neurology. 2015.
PMID: 25809301
OBJECTIVE: We performed a real-life observation of patients with Parkinson disease (PD) who received duodenal levodopa infusion (DLI) to determine which adverse events caused treatment discontinuation and when such events occurred. ...At …
OBJECTIVE: We performed a real-life observation of patients with Parkinson disease (PD) who received duodenal levodo …
Duodenal Levodopa Infusion for Long-Term Deep Brain Stimulation-Refractory Symptoms in Advanced Parkinson Disease.
Clin Neuropharmacol. 2017 May/Jun;40(3):103-107. doi: 10.1097/WNF.0000000000000216.
Clin Neuropharmacol. 2017.
PMID: 28452905
OBJECTIVES: This study assesses the effect of levodopa/carbidopa intestinal infusion gel (LCIIG) as an additional treatment in patients with advanced idiopathic Parkinson disease (PD) previously treated with deep brain stimulation (DBS). ...Cont …
OBJECTIVES: This study assesses the effect of levodopa/carbidopa intestinal infusion gel (LCIIG) as an additional treatment …
Levodopa infusion in Parkinson's disease: Individual quality of life.
Acta Neurol Scand. 2020 Sep;142(3):248-254. doi: 10.1111/ane.13260. Epub 2020 May 22.
Acta Neurol Scand. 2020.
PMID: 32383152
OBJECTIVES: Parkinson's disease (PD) features both motor and non-motor symptoms that substantially impact quality of life (QoL). Levodopa-carbidopa intestinal gel (LCIG) reduces motor complications and improves some non-motor symptoms in advanced PD (A …
OBJECTIVES: Parkinson's disease (PD) features both motor and non-motor symptoms that substantially impact quality of li …
Pharmacokinetic optimisation in the treatment of Parkinson's disease : an update.
Clin Pharmacokinet. 2006;45(2):109-36. doi: 10.2165/00003088-200645020-00001.
Clin Pharmacokinet. 2006.
PMID: 16485914
Review.
Pharmacotherapy for Parkinson's disease is focused on dopaminergic drugs, mainly the dopamine precursor levodopa and dopamine receptor agonists. ...The long-duration of response to levodopa, which is evident in early Parkinson's …
Pharmacotherapy for Parkinson's disease is focused on dopaminergic drugs, mainly the dopamine precursor levodopa …
Application of the concept of continuous dopaminergic stimulation for the management of Parkinson's disease.
Neurosci Bull. 2013 Oct;29(5):661-9. doi: 10.1007/s12264-013-1329-8. Epub 2013 Mar 20.
Neurosci Bull. 2013.
PMID: 23512740
Free PMC article.
Review.
Continuous dopaminergic stimulation (CDS) is a prominent therapeutic concept for the treatment of Parkinson's disease (PD), which proposes that continuous brain dopamine-receptor stimulation, rather than intermittent doses of oral L-dopa, prevents or m …
Continuous dopaminergic stimulation (CDS) is a prominent therapeutic concept for the treatment of Parkinson's diseas …
Advances in the delivery of treatments for Parkinson's disease.
Expert Opin Drug Deliv. 2005 Nov;2(6):1059-73. doi: 10.1517/17425247.2.6.1059.
Expert Opin Drug Deliv. 2005.
PMID: 16296809
Review.
Innovative drug delivery in Parkinson's disease (PD) has the potential to reduce or avoid many side effects of current treatment, such as wearing-off type fluctuations, dyskinesia, on-off phenomena or bouts of motor freezing. ...An alternative approach …
Innovative drug delivery in Parkinson's disease (PD) has the potential to reduce or avoid many side effects of current …
Cite